Cellectis to Present Data at the 2018 ASGCT Annual Meeting NEW YORK--(BUSINESS WIRE)

to Present Data at the 2018 ASGCT Annual Meeting

NEW YORK--(BUSINESS WIRE)--May 10, 2018--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq:

CLLS), a clinical-stage biopharmaceutical company focused on developing

immunotherapies based on gene-edited allogeneic CAR T-cells (UCART),

announced today that three posters regarding the Company's allogeneic

off-the-shelf CAR-T product candidates and one poster associated with

the Company's technology will be presented at the American Society of

Gene and Cell Therapy (ASGCT) Annual Meeting to be held from May 16 to

19, 2018, in Chicago, Illinois.

Universal CAR T-Cells Targeting CS1 (UCARTCS1) for the Treatment

Agn s Gouble1, Roman Galetto1,

Rohit Mathur3, Stephanie Filipe1, Isabelle

Chion-Sotinel1, Jing Yang3, Jin He3,

Robert Z. Orlowski3, Sattva S. Neelapu3 and

1Cellectis SA, 8 rue de la

croix Jarry, 75013 Paris, France

2Cellectis, Inc., 430

East 29th Street, 10016 New York, NY

Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center,

1515 Holcombe Blvd., Houston, TX 77030

Cancer - Targeted Gene & Cell Therapy I

May 16, 2018 at 5:30 PM - Stevens Salon C, D

Repurposing endogenous immune pathways to improve chimeric

antigen receptor T-cells potency

M. Sachdeva1, B. Busser1, S. Temburni1,

A. Juillerat1, L. Poirot2, P.

Duchateau2, J. Valton1;

2Cellectis, Paris, France

May 18, 2018 at 5:45 PM - Stevens Salon C, D

Engineering CAR T-Cells with an Integrated off Switch to Enhance

Alexandre Juillerat1, Diane Tkach1, Brian

W. Busser1, Sonal Temburni1, Julien Valton1,

Aymeric Duclert2, Laurent Poirot2 and Philippe

1Cellectis, Inc., 430E, 29th Street,

2Cellectis SA, 8 rue de la Croix Jarry,

Cancer - Immunotherapy, Cancer Vaccines

Friday, May 18, 2018 at 5:45 PM - Stevens Salon C, D

Presented by Allogene Therapeutics, Inc.:

Cynomolgus macaque gene-edited CAR T-cell platform: towards a

reliable in vivo allogeneic model to assess safety and Efficacy

Diego A. Vargas-Inchaustegui1, Rory Dai1,

Alexandre Juillerat2, Christopher Do1, Kris Poulsen1,

Thomas Pertel1, Barbra Sasu1

Therapeutics, Inc., South San Francisco, CA,

Cancer - Targeted Gene & Cell Therapy I

May 16, 2018 at 5:30 PM - Stevens Salon C, D

Abstracts are available on the ASGCT website. The 4 posters to be

presented at the 2018 ASGCT Annual Meeting will be available on the

Cellectis website after May 19, 2018.

Cellectis is a clinical-stage biopharmaceutical company focused on

developing a new generation of cancer immunotherapies based on

gene-edited T-cells (UCART). By capitalizing on its 18 years of

expertise in gene editing - built on its flagship TALEN technology and

pioneering electroporation system PulseAgile - Cellectis uses the power

of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering

technologies, Cellectis' goal is to create innovative products in

multiple fields and with various target markets.

Cellectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext

Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN is a registered trademark

This press release contains "forward-looking" statements that are based

on our management's current expectations and assumptions and on

information currently available to management. Forward-looking

statements involve known and unknown risks, uncertainties and other

factors that may cause our actual results, performance or achievements

to be materially different from any future results, performance or

achievements expressed or implied by the forward-looking statements.

Further information on the risks factors that may affect company

business and financial performance, is included in Cellectis' Annual

Report on Form 20-F for the year ended December 31, 2017 and subsequent

filings Cellectis makes with the Securities and Exchange Commission from

time to time. Except as required by law, we assume no obligation to

update these forward-looking statements publicly, or to update the

reasons actual results could differ materially from those anticipated in

the forward-looking statements, even if new information becomes

available in the future.

For further information, please contact:

Jennifer Moore, 917-580-1088

Caitlin Kasunich, 212-896-1241

Simon Harnest, 646-385-9008

Strategy and Finance